Manufacturing – Page 2

Sanofi Announces $20 Billion US Investment Over Five Years

2 months ago talkbio0Tagged Big Pharma, development aspects, domestic partnerships, Drug Industry, Investments, Manufacturing, research, sanofi, Surgical construction, tariffs, U.S.

Sanofi; $20 billion investment; US pharmaceutical industry; manufacturing; research and development; tariffs; job creation; Big Pharma; domestic partnerships

‘Now is not the time to retreat’: BMS CEO blasts Trump admin tariffs, health reforms amid $40B US investment pledge

3 months ago talkbio0Tagged Drug Industry, Health Care Reform, Home environment, Manufacturing, Myers, pharmaceutical manufacturing, pharmaceutical tariffs, squibb, Trump tariffs, U.S.

Bristol Myers Squibb, Trump tariffs, pharmaceutical manufacturing, domestic investment, pharmaceutical industry, US manufacturing, healthcare reform, pharmaceutical tariffs

AstraZeneca’s China woes recede as focus shifts to upcoming readouts

3 months ago talkbio0Tagged Acquisition, Beijing, biotech, China, China legal issues resolution, FibroGen, Fine - adjective, global strategic R&D center, Investments, Manufacturing, partnerships, R&D

$2.5 billion R&D investment in Beijing, Global strategic R&D center, China legal issues resolution, Biotech partnerships, Manufacturing expansion, $8 million potential fine, FibroGen China acquisition

Pfizer CEO Bourla suggests pharma tariffs will focus on US adversaries, not allies

3 months ago talkbio0Tagged Administration occupational activities, Albert, Bourla, chain concerns, Evaluation, Investments, Manufacturing, National Security, pharmaceutical tariffs, Policy, Sectioning technique, TNFRSF19 gene, Transplant Registry Unified Management Program

Pharmaceutical tariffs, Section 232 investigation, Albert Bourla, national security, trade policy, manufacturing investments, Trump administration, supply chain concerns

U.S. Biotechs Reveal Tariff Exposure as Trade Inquiry Signals Imminent Pharmaceutical Tariffs

3 months ago talkbio0Tagged Evaluation, global supply chain, Impact food supplement, Import, Manufacturing, pharmaceutical ingredients, pharmaceutical tariffs, Policy, regulatory, reshoring, Sectioning technique, supply chain exposure, TNFRSF19 gene, United States

U.S. biotech, pharmaceutical tariffs, Section 232 investigation, supply chain exposure, trade policy, import costs, reshoring manufacturing, drug pricing, global supply chain, pharmaceutical ingredients, regulatory impact

Trump Tariffs Poised to Hit Drug Tool and Packaging Manufacturers: Industry Faces Rising Costs and Supply Chain Challenges

4 months ago talkbio0Tagged alpha 1-antitrypsin, Biopharma trade war, Drug Industry, Drug packaging industry, Generic Drugs, Impact food supplement, lobbying, Manufacturing, Market, onshoring, Pharmaceutical Supply Chain, pharmaceutical tariffs, Supply chain disruption, Trump tariffs, U.S., United States

Trump tariffs , Drug packaging industry , Pharmaceutical supply chain , API manufacturing costs , Biopharma trade war , U.S. manufacturing onshoring , Generic drugs market impact , Pharmaceutical tariffs , Supply chain disruption , Pharmaceutical industry lobbying

Trump’s Looming Pharmaceutical Tariffs: Uncertainty and Potential Impact

4 months ago talkbio0Tagged Manufacturing, pharmaceutical tariffs, Policy, Prices, TNFRSF19 gene, Transplant Registry Unified Management Program

Trump, pharmaceutical tariffs, trade policy, drug prices, manufacturing, supply chain

Johnson & Johnson Announces $55 Billion Investment in U.S. Manufacturing and Innovation

4 months ago talkbio0Tagged aligns, announcement, Benefit, capabilities, commitment, Corporation, domestic pharmaceutical industry, Increased, innovation, Investments, J&J 's, Manufacturing, Surgical construction, trends qualifier, United States

This major investment demonstrates J&J’s commitment to expanding its U.S. manufacturing and innovation capabilities, with potential benefits for job creation and the domestic pharmaceutical industry. The announcement aligns with broader trends of increased U.S. manufacturing investment by large corporations in recent years.